The EU Commission plans on reviewing a transaction even though EU and national turnover thresholds are not reached (Illumina / GRAIL)

KEYWORDS
Reference

EU Commission, Illumina / GRAIL, Press release, 20 April 2021

In a controversial move, the European Commission (the Commission) announced on 20 April 2021 that it would review the proposed acquisition of cancer detection test start-up Grail by genomics firm Illumina, both of the US. The Commission acted on a request of France, which was backed by three further EU Member States (Belgium, Greece, and The Netherlands) as well as EEA countries Iceland and Norway, under powers conferred to it by Article 22 of the EU Merger Control Regulation (Article 22).

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

  • Van Bael & Bellis (Brussels)
    Belgium 37 contributions 20164 visits
  • Van Bael & Bellis (Brussels)
    Belgium 142 contributions 49291 visits
  • Van Bael & Bellis (Brussels)
    Belgium 46 contributions 23079 visits
  • Van Bael & Bellis (Brussels)
    Belgium 45 contributions 22180 visits

Quotation

Michael Clancy, Peter L'Ecluse, Catherine Longeval, Koen T'Syen, The EU Commission plans on reviewing a transaction even though EU and national turnover thresholds are not reached (Illumina / GRAIL), 20 April 2021, e-Competitions Gun jumping, Art. N° 102436

Visites 219

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues